Dr Muhammad usman ghani

INJ MOUNJARO FOR MASLD/MASH

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis | New England Journal of Medicine

Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis | NEJM Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of t...

Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis - Clinical Gastroenterology and Hepatology https://share.google/IoqxpD2XoJTuHKQko

Indication of RESMITEROM in MASLD/MASH .
In future , GLP-1 agonists will be given .

Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis Metabolic dysfunction–associated steatotic liver disease affects 1 in 4 people in the United States and western Europe, with an important proportion developing metabolic dysfunction–associated steatohepatitis (MASH), the progressive subtype of metabolic dysfunction–associated steatotic live...

Tirzepatide significantly improves insulin sensitivity within 12 weeks, indicating an early metabolic effect that is not solely attributable to weight loss link.springer.com/article/10.100…

Page unavailable | SpringerLink Page unavailable The information you're looking for cannot be found, it may be temporarily unavailable or permanently removed. Try refreshing the page, or returning to our homepage. If the problem continues, please let us know.

https://www.mdpi.com/2813-0618/4/3/14

Future of resmetirom and semaglutide in MAFLD / MASH .

The Comparative Safety and Efficacy of Resmetirom and Semaglutide in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly encompassed under nonalcoholic fatty liver disease (NAFLD), is a growing global health burden associated with progression to cirrhosis and hepatocellular carcinoma. Resmetirom, a thyroid hormone receptor-β (THR...

22 لاکھ مربع میل پر پھیلے ھوئے اسلام کو جب 10 محرم الحرام میں نچوڑا گیا تو صرف 72 جانثار نکلے!.